Literature DB >> 18490620

Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain.

Connie Marras1, Anthony Lang.   

Abstract

Recent years have seen major changes in our understanding of Parkinson disease (PD), challenging conventional wisdom, much of which was established during the Decade of the Brain. In this article, we highlight important changes in our understanding of PD in six general categories: definition, etiology, pathology, pathogenesis, clinical features, and therapeutics.

Entities:  

Mesh:

Year:  2008        PMID: 18490620     DOI: 10.1212/01.wnl.0000312515.52545.51

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  CSF markers of neurodegeneration in Parkinson's disease.

Authors:  Hana Přikrylová Vranová; Jan Mareš; Martin Nevrlý; David Stejskal; Jana Zapletalová; Petr Hluštík; Petr Kaňovský
Journal:  J Neural Transm (Vienna)       Date:  2010-08-21       Impact factor: 3.575

Review 2.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

3.  Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.

Authors:  Amnon C Sintov; Haim V Levy; Igor Greenberg
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

4.  Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.

Authors:  Senthil Selvaraj; Yuyang Sun; John A Watt; Shouping Wang; Saobo Lei; Lutz Birnbaumer; Brij B Singh
Journal:  J Clin Invest       Date:  2012-03-26       Impact factor: 14.808

5.  Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease.

Authors:  Cristina Malagelada Grau; Lloyd A Greene
Journal:  Methods Mol Biol       Date:  2012

Review 6.  Basic science in Parkinson's disease: its impact on clinical practice.

Authors:  Jörg B Schulz; Manfred Gerlach; Gabriele Gille; Wilfried Kuhn; Martina Müngersdorf; Peter Riederer; Martin Südmeyer; Albert Ludolph
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

7.  Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

Authors:  Cristina Malagelada; Zong Hao Jin; Vernice Jackson-Lewis; Serge Przedborski; Lloyd A Greene
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

Review 8.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

9.  Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease.

Authors:  J Eric Ahlskog
Journal:  Parkinsonism Relat Disord       Date:  2009-10-07       Impact factor: 4.891

10.  Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial.

Authors:  Bahram Yousefi; Vahid Tadibi; Ali Fathollahzadeh Khoei; Ali Montazeri
Journal:  Trials       Date:  2009-08-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.